2. Search Result
Search Result
Results for "

folate receptors

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

2

Fluorescent Dye

16

Biochemical Assay Reagents

3

Peptides

3

Inhibitory Antibodies

4

Click Chemistry

10

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13728
    Plevitrexed

    ZD 9331; BGC9331

    		 Thymidylate Synthase Cancer
    Plevitrexed (ZD 9331; BGC 9331) is an orally active and potent thymidylate synthase (TS) inhibitor with a Ki of 0.44 nM. Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is used for gastric cancer in clinical . Plevitrexed is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Plevitrexed
  • HY-10822A
    ONX 0801 trisodium

    BGC 945 trisodium; Idetrexed trisodium; CB 300945 trisodium

    		 Thymidylate Synthase Cancer
    ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors .
    ONX 0801 trisodium
  • HY-147699
    FRα-IN-1

    		Antifolate Cancer
    FRα-IN-1 (Compound 4) is a tumor-targeting agent. FRα-IN-1 shows selective anticancer activity towards folate receptors (FRα and FRβ) expression cells .
    FRα-IN-1
  • HY-167412
    PLLA5000-PEG2000-FOL

    		Biochemical Assay Reagents Others
    PLLA5000-PEG2000-FOL is a polylactic acid derivative. Polylactic acid derivatives have strong binding affinity to folate receptors and clear biodegradability. PLLA5000-PEG2000-FOL can be used in drug delivery research .
    PLLA5000-PEG2000-FOL
  • HY-167415
    PLLA10000-PEG5000-FOL

    		Biochemical Assay Reagents Others
    PLLA10000-PEG5000-FOL is a polylactic acid derivative. Polylactic acid derivatives have strong binding affinity to folate receptors and clear biodegradability. PLLA10000-PEG5000-FOL can be used in drug delivery research .
    PLLA10000-PEG5000-FOL
  • HY-167413
    PLLA20000-PEG5000-FOL

    		Biochemical Assay Reagents Others
    PLLA20000-PEG5000-FOL is a polylactic acid derivative. Polylactic acid derivatives have strong binding affinity to folate receptors and clear biodegradability. PLLA20000-PEG5000-FOL can be used in drug delivery research .
    PLLA20000-PEG5000-FOL
  • HY-167411
    PLLA5000-PEG5000-FOL

    		Biochemical Assay Reagents Others
    PLLA5000-PEG5000-FOL is a polylactic acid derivative. Polylactic acid derivatives have strong binding affinity to folate receptors and clear biodegradability. PLLA5000-PEG5000-FOL can be used in drug delivery research .
    PLLA5000-PEG5000-FOL
  • HY-167416
    PLLA10000-PEG2000-FOL

    		Biochemical Assay Reagents Others
    PLLA10000-PEG2000-FOL is a polylactic acid derivative. Polylactic acid derivatives have strong binding affinity to folate receptors and clear biodegradability. PLLA10000-PEG2000-FOL can be used in drug delivery research .
    PLLA10000-PEG2000-FOL
  • HY-167414
    PLLA20000-PEG2000-FOL

    		Biochemical Assay Reagents Others
    PLLA20000-PEG2000-FOL is a polylactic acid derivative. Polylactic acid derivatives have strong binding affinity to folate receptors and clear biodegradability. PLLA20000-PEG2000-FOL can be used in drug delivery research .
    PLLA20000-PEG2000-FOL
  • HY-P10501
    FRα-targeting peptide C7

    		Antifolate Cancer
    FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7
  • HY-P10501A
    FRα-targeting peptide C7 TFA

    		Antifolate Cancer
    FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7 TFA
  • HY-P99612
    Farletuzumab ecteribulin

    MORAb-202

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
    Farletuzumab ecteribulin
  • HY-115873
    Folate-MS432

    		PROTACs Cancer
    Folate-MS432, a PROTAC, is capable of degrading MEKs in a folate receptor-dependent manner in cancer cells.
    Folate-MS432
  • HY-144009
    DSPE-PEG-Folate, MW 3350

    		Liposome Cancer
    DSPE-PEG-Folate, MW 3350 is a PEG derivative containing folic acid. DSPE-PEG-Folate has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate form micelles/lipid bilayer and can be used to targeted drug delivery system research .
    DSPE-PEG-Folate, MW 3350
  • HY-W440888
    DSPE-PEG-Folate, MW 2000

    DSPE-PEG(2000) folate

    		 Liposome Others
    DSPE-PEG-Folate, MW 2000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 2000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 2000 form micelles/lipid bilayer and can be used to targeted drug delivery system research.
    DSPE-PEG-Folate, MW 2000
  • HY-W440890
    DSPE-PEG-Folate, MW 5000

    		Liposome Cancer
    DSPE-PEG-Folate, MW 5000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 5000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 5000 form micelles/lipid bilayer and can be used to targeted drug delivery system research .
    DSPE-PEG-Folate, MW 5000
  • HY-128937
    EC1454

    		Liposome Folate Receptor (FR) Cancer
    EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .
    EC1454
  • HY-155883
    mPEG-amine (MW 3400)

    mPEG-NH2 (MW 3400)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 3400) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 3400)
  • HY-155880
    mPEG-amine (MW 350)

    mPEG-NH2 (MW 350)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 350) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 350)
  • HY-155881
    mPEG-amine (MW 550)

    mPEG-NH2 (MW 550)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 550) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 550)
  • HY-155882
    mPEG-amine (MW 750)

    mPEG-NH2 (MW 750)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 750) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 750)
  • HY-155884
    mPEG-amine (MW 4000)

    mPEG-NH2 (MW 4000)

    		 Biochemical Assay Reagents Cancer
    mPEG-amine (MW 4000) can be used to synthesize folate-conjugated polymer micelles for encapsulating anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 4000)
  • HY-13615
    Folate-FITC

    EC-17

    		 Fluorescent Dye Others Cancer
    Folate-FITC (EC-17) is a folic acid derivative that binds to fluorescein isothiocyanate (FITC) to give it fluorescent labeling properties. Folate-fitc is used to induce the formation of pseudo-immunological synapses between anti-FITC CAR T cells and target cells expressing Folate receptors (FRα or FRβ). Folate-FITC can be used to develop controlled CAR-T cell therapies for research in non-small cell lung cancer (NSCLC) .
    Folate-FITC
  • HY-P99225
    Mirvetuximab

    M9346A

    		 Antifolate Cancer
    Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
    Mirvetuximab
  • HY-128939
    EC0488

    		Antifolate Cancer
    EC0488 is used to synthesize EC0531 with folate receptor (FR)-specific and anti-tumor activities .
    EC0488
  • HY-162975
    NVP-EVS459 (175Lu)

    		Antifolate Radionuclide-Drug Conjugates (RDCs) Cancer
    NVP-EVS459 (175Lu) is a folate receptor targeting radio-conjugate, and can be used for cancer research.
    NVP-EVS459 (175Lu)
  • HY-132258A
    Mirvetuximab soravtansine (solution)
    1 Publications Verification

    IMGN853 (solution)

    		 Antibody-Drug Conjugates (ADCs) Antifolate Cancer
    Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
    Mirvetuximab soravtansine (solution)
  • HY-129880
    Desacetylvinblastine hydrazide

    Deacetylvinblastine hydrazide; DAVLBH

    		 Microtubule/Tubulin Cancer
    Desacetylvinblastine hydrazide (Deacetylvinblastine hydrazide; DAVLBH) is an active component of EC145, a folate-targeted drug conjugate. Desacetylvinblastine hydrazide interferes with the formation of the mitotic spindle, and thus inhibits cell division and leads to cell death. Desacetylvinblastine hydrazide exhibits antitumor activity against folate receptor (FR)-positive tumor .
    Desacetylvinblastine hydrazide
  • HY-W115607
    PEG-bis-amine (MW 8000)

    Poly(ethylene glycol)-bis-amine (MW 8000)

    		 Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 8000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    PEG-bis-amine (MW 8000)
  • HY-W591632
    PEG-bis-amine (MW 1000)

    Poly(ethylene glycol)-bis-amine (MW 1000)

    		 Biochemical Assay Reagents Cancer
    PEG-bis-amine (MW 1000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    PEG-bis-amine (MW 1000)
  • HY-114306
    EC0489

    		Antifolate Cancer
    EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor . Small molecule-agent conjugate (SMDC) .
    EC0489
  • HY-D2523
    Cy3-PEG-FA (MW 2000)

    		Folate Receptor (FR) Fluorescent Dye
    Cy3-PEG-FA (MW 2000) is a fluorescent folate-PEG derivative with excitation/emission wavelengths of ~550 nm/~570 nm. Cy3-PEG-FA (MW 2000) can be readily traced by its intense red fluorescent signal. Cy3-PEG-FA (MW 2000) can be used for cell imaging, folate receptor targeting and detection.
    Cy3-PEG-FA (MW 2000)
  • HY-10822
    Idetrexed

    BGC 945; ONX-0801

    		 Thymidylate Synthase Others
    Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L .
    Idetrexed
  • HY-13615A
    EC-17 disodium salt

    		Fluorescent Dye Cancer
    EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520 nm.
    EC-17 disodium salt
  • HY-P99153
    Farletuzumab

    MORAb-003

    		 Antibiotic Cancer
    Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
    Farletuzumab
  • HY-D1716
    S0456

    		Fluorescent Dye Drug Intermediate Cancer
    S0456 is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38 (HY-139579). S0456 is connected to the modified folic acid to form OTL 38, endowing OTL 38 with good optical properties, high affinity, and specificity. S0456 can be used in the research of tumor optical imaging agents .
    S0456
  • HY-148194
    SC239

    		Drug-Linker Conjugates for ADC Cancer
    SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    SC239
  • HY-10819
    AG2034

    		Antifolate Cancer
    AG2034 is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), with a Ki of 28 nM against human GARFT, and it binds with high affinity to the folate receptor (Kd of 0.0042 nM). Additionally, AG2034 is a substrate for rat liver folylpolyglutamate synthetase, with a Km of 6.4 µM. AG2034 inhibits the growth of L1210 and CCRF-CEM cells, with IC50 values of 4 nM and 2.9 nM, respectively, and it has demonstrated antitumor activity in xenograft models such as 6C3HED .
    AG2034
  • HY-P10762
    CBP-1008

    LDC 10B

    		 Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    CBP-1008